Dr. Veromaa has a wealth of commercial success and drug discovery experience. Prior to joining Domainex in 2017, Timo was President and CEO of Biotie Therapies Corporation for over 11 years until its acquisition by Acorda Therapeutics in 2016. During this period he executed several successful M&A transactions and raised over EUR 200 million in equity and R&D funding, and achieved significant growth in the company, including the launch of Selincro® (an opioid antagonist), and a listing on the US Nasdaq stock exchange.
During his earlier career he was a Medical Director of Schering Ltd. in Finland, Senior Scientist and Project Director at Collagen Corporation and a Postdoctoral Fellow at Stanford University in California. He is a medical doctor with a PhD in immunology from the University of Turku, Finland.